Penalised for having cancer
Many cancer patients are being tipped into poverty as a direct result of their illness, which adds stress and misery to an already very difficult situation. In this editorial, Cancer World looks at the many [more]
November 2012
Andreas Engert: Learning from Hodgkin’s
Hodgkin’s patients survive for longer but with more serious and lasting damage than almost any other group of cancer patients. Finding ways to address the problems of both current and future survivors can [more]
Testing the testers
Treating the right patient with the right therapy at the right time depends on having the right picture of every patient’s key biological markers. A number of initiatives are now springing up across Europe to [more]
Late diagnosis: Why does it happen? How can we do better?
When GPs fail to identify symptomatic cancers on time it can be fatal for patients and frustrating for the specialists who treat them. In this article, GP Tina Eriksson and gastrointestinal cancer specialist Eric Van [more]
The origin of a special success
Cancer genetics is intriguing, exciting and offers hope for real progress in treatment, but try telling that to non-scientists. Clive Cookson, science editor at the Financial Times, did just that. His article, explaining the evolutionary [more]
OECI accreditation: is yours a top-class cancer centre?
Whether you work at a cancer unit, a cancer centre or a comprehensive cancer centre, applying for OECI accreditation is a good way to find out how your institute compares with the best, and get [more]
Lungscape: a living lung laboratory
The potential for personalising lung cancer therapies is expanding rapidly. The challenge now is how to turn that potential into reality as fast as possible so patients can reap the benefits. A network of cancer [more]
Gastro-oesophageal cancer is CROSSing over so hard to do?
Suboptimal studies had established preoperative chemoradiation as the preferred strategy in the management of localised oesophageal cancer (LEC) and gastro-oesophageal cancer. The recent CROSS trial has now demonstrated considerable benefit from preoperative chemoradiation over surgery [more]
Cetuximab dosing by rash is the scaling of EVEREST meaningful?
The small EVEREST trial has shown that the concept of guiding cetuximab dose escalation using the clinical parameter of acneiform skin rash is safe. However, as no significant increase of cetuximab efficacy could be observed, [more]
